

SORBONNE

UNIVERSITÉ

Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (BIO101)

<u>Waly Dioh</u>¹, Cendrine Tourette¹, Carole Margalef¹, René Lafont¹², Philippe Dupont¹, Pierre Dilda¹, Stanislas Veillet¹, Samuel Agus¹ and Susanna Del Signore³

¹ Biophytis, UMPC – BC9, 4 place Jussieu, 75005 Paris, France. ² Sorbonne Université, UPMC Univ Paris 06, Paris-Seine Biology Institut (BIOSIPE), CNRS, 75005 Paris, France. 3 Bluecompanion Itd, London, United Kingdom

Introduction

Sarcopenia, is characterized by the loss of muscle mass and muscle strength leading to a global muscle functional impairment and physical disability. Biophytis has developed the drug candidate Sarconeos (BIO101), purified at 97% of 20 hydroxyecdysone (20E), from the edible plant Stemmacantha carthamoides. BIO101 has a potential to improve muscle quality and function in *in vitro* and *in vivo* models and accelerates differentiation and enhances mitochondrial function in skeletal muscle cells (see Poster number 4-011). SARA-OBS, is the ongoing observational study dedicated to characterize the population for SARA-INT, the interventional study with the investigational drug BIO101. Both studies are hosted in SARA-Data, an innovative platform for clinical trials. Each of SARA-OBS and SARA-INT study is a 6-month multicenter, clinical trial enrolling community-dwelling persons in Europe and USA and aged 65 years and older at risk of mobility disability. The main objective of SARA-INT is to evaluate 2 selected doses of BIO101 in the targeted sarcopenic population.

SARA-OBS Main characteristics

Baseline characteristics of SARA-OBS included patients

Characteristics	Absolute	Standard	Characteristics		Mean	SD	
Characteristics		deviation		Physical function (PF)	52.32	26.08	
Age	79.29	7.39		Role, physical (RP)	42.42	34.47	
BMI	29.3	6.8		Role, emotional (RE)	68.33	29.88	
Male:Female (%)	39:61	NA	SF36	Bodily pain (BP)	62.29	25.70	
SPPB	6.12	1.83		Mental health (MH)	68.88	21.82	
Gait Speed in				Vitality (VT)	56.47	21.78	
SPPB (sec)	0.70	0.29		Social function (SF)	73.36	24.96	
Chair stand	1.73	0.97		General health (GH)	56.87	19.07	
Appendicular Lean Mass	17.17	5.07	Ma	ximum Grip strength (kg)	26.7	13,0	
(ALM)				Men	31,6	12,8	
Men	21.30	4.81					
Women	14.28	2.69			20)0	12,0	
ALM/BMI	0.59	0.12					
Men	0.69	0.10					
Women	0.52	0.09					
6MWD	295.14	95.99					
400M (min)	8.41	3.20					
Gait speed 400M (m/sec)	0.88	0.27					

SARA-INT

SARA-INT objectives

Primary objectives:

• Evaluate the effect of two daily doses of BIO101 versus placebo on gait speed at the 400MW test.

Key secondary objectives

 Compare the change from baseline of the Patient Reported Outcome (PRO): The Physical Function Domain (PF-10) of the Short Form Health Survey (SF-36).
 Rising from a chair

SARA-OBS

Sarcopenia definition used the criteria of the Foundation of NIH (Studenski et al., 2014) with the risk of mobility disability operationalised using the Short Physical Performance Battery (SPPB; Guralnik et al., 1994)

- Absolute ALM (< 19.75 in men and < 15.02 in women) and ALM/BMI (< 0.789 in men, < 0.512 in women) measured by DXA.
- SPPB ≤ 8/12;

- As seen in other large sarcopenia clinical trials, patients showed high BMI allowing to incorporate sarcopenic obese patients.
- 400 m gait speed is similar to the Life study (0.83 m/s at baseline; Pahor et al., 2014).
- Mean SPPB is rather low (6.12/12), corresponding to patients at risk of mobility disability and comparable to other sarcopenia studies (Life study with 7.4±1.6 in the physical activity group, Pahor et al., 2014 and SPRINTT with 6.7±1.4, Marzetti et al., 2018).
- Gait speed SPPB is <0.8 m/s, and fits the EWGSOP definition of sarcopenia and is comparable to value in SPRINTT.
- ALM/BMI in men is lower than the FNIH threshold (0.69 vs 0.789) but is similar in women (0.52 vs 0.52).
 The 6MWD at 295.14 meters was expected for patients of the mean age (79.29 years) and BMI (29.3). This is low compared to data from sarcopenic patients (575.7±91.8 in men and 523.3±83.4 in women; Pederso-Chamizo et al., 2014) or (461.8 (108.6) in men and 392.8 (118.2) in women; (Gouvea et al., 2013).
 Hand Grip strength was average higher compared to cut points of revised EWGSOP2 (Cruz–Jentoft et al., 2018). Grip strength is <27 kg for 31 % of men, and < 16 kg for 26 % of women.

Other Secondary, Tertiary and Exploratory Objectives

- Body composition; Muscle strength; Stair climbing; SPPB;
- PRO (SF-36, SarQoL, TSD-OC);
- Actimetry; Biomarkers (Myostatin; PIIINP; IL-6; HsCRP; Aldosterone; Renin; Isolated PBMC, etc....)

Target population

334 sarcopenic patients reporting loss of physical function and considered at risk of mobility disability will be recruited for the SARA-INT study.

The recruitment criteria are similar to the Foundation of NIH (Studenski et al., 2014)


- SPPB ≤ 8/12
- Absolute ALM (< 19.75 in men and < 15.02 in women)
- and ALM/BMI (< 0.789 in men, < 0.512 in women) by DXA

SARA-INT preliminary results

Characteristics	Absolute	Standard deviation	Characteristics	Absolute	Standard deviation	
Age	79.33	6.43	ALM/BMI	0.65	0.13	
BMI	28.2	8.6	Men	0.72	0.07	
Male:Female (%)	61:39	NA	Women	0.53	0.12	
SPPB	7.78	2.02	6MWD	306.32	96.61	
Gait Speed in	0.85	0.21	400M (min)	8.33	1.96	
SPPB (sec)	0.85	0.21	Gait speed 400M	0.85	0.21	
Chair stand	1.53	0.74	(m/sec)	0.85	0.21	
Appendicular	17.87	5.45				
Lean Mass (ALM)	17.07	5.45				
Men	20.34	5.3				
Women	13.99	3.01				

• As of today, 18 patients are randomized

SARA-OBS Clinical study design



Main objective

 Characterize the target population in Europe and USA and estimate the prevalence of sarcopenia including sarcopenic obesity in the study sample.


Primary endpoint:

- 400 m walking test gait speed
- Patient reported outcomes (PROs): Short Form Health Survey (SF-36) and Sarcopenia Quality of Life (SARQOL) and TSD-OC for BMI ≥ 30

Secondary and exploratory endpoints

- Body composition, Gait speed; Grip strength, 6 minutes walk.
- Actimetry; Biomarkers (Myostatin; PIIINP; IL-6; HsCRP; Aldosterone; Renin; Isolated PBMC, etc...)

SARA-OBS Workflow



SARA-INT

SARA-INT clinical study design

- SARA-INT is an EU and US double-blind, placebo controlled, randomized INTerventional Clinical trial.
- SARA-INT aims to evaluate safety and efficacy of Sarconeos (BIO101), the investigational drug orally administered for 6 month.
- Most of the sites that participated in SARA-OBS, and additional sites are currently being selected.
- All the patients recruited in the SARA-OBS study are ready to be randomized in the SARA-INT study.
- A pharmacokinetic sub study in Europe is also included in the SARA-INT study

- 39% of randomized patients are subjects coming form SARA-
- OBS clinical study
- Overall, SARA-INT population shares the same characteristics as SARA-OBS.
- Mean SPPB score and 400 m gait speed are very similar to the LIFE study (7.78 vs 7.4 and 0.85 vs 0.83 m/s respectively)
- ALM/BMI in men is lower than the FNIH threshold (0.72 vs 0.789) but is similar in women (0.53 vs 0.52).
- The mean 6MWD at 306.32 meters is low compared to data of sarcopenic patients from other studies (mean from 461.8 to 575.7).

Conclusions

- Like for other sarcopenia observational studies, SARA-OBS confirmed recruitment opportunities in sarcopenia trials when using the FNIH criteria (Studenski et al., 2014, ALM/BMI<0.789 in Men and <0.512 in Women) and Absolute ALM <19.75 kg in men and <15.02 kg in women.
- Similar to SPRINTT study, we selected low performers at SPPB≤8/12 as an index of mobility disability risk.
- Baseline characteristics are comparable to other sarcopenia studies (Life study, Pahor et al., 2014; SPRINTT Marzetti et al., 2018).
- Preliminary analysis confirmed that that target population derived from SARA-OBS is eligible for the SARA-INT phase 2 interventional study.
- SARA-INT clinical trial received all due authorisations from Competent Authorities in USA and Belgium.


<u>References</u>

Screened N=869

> Excluded N=651 SPPB> 8: N=364 ALM/BMI>0.789 or 0.512: or ALM>19.75 or 15.02: N=199 Other: N=88

Included N=218

- 50 % of the prescreened patients were not retained. Main reasons were the absence of reported mobility issue and conditions included in SARA-OBS exclusion criteria list.
- Prescreening failure (Prescreened vs included) was rather high: only 11 % of prescreened were selected.
- Screening failure was high, and only 25 % of screened patients were included. Similar or even lower rates were also observed in other sarcopenia clinical trials: 5% (Fielding et al., 2017a), 11% (Fielding et al., 2017b) and 23% (Marzetti et al., 2018)
- Main reasons of screening failure are SPPB > 8 (56%), ALM/BMI > 0.789 or > 0.512 and ALM > 19.75 kg or > 15.02 kg (31%), other screening failures representing 14%.



- Fielding RA, Travison TG, Kirn DR et al. Effect of Structured Physical Activity and Nutritional Supplementation on physical Function in Mobility-Limited Older ADULTS: results from the VIVE2 Randomized trial. J Nutr Healthy Aging. 2017. Online First Articles. 1-7
- Fielding RA, Guralnik JM, King AC, Pahor M, McDermott M, Tudor-Locke C, Manini TM, Glynn NW, Marsh PA, Axtell RS, Hsu Fang-Chi, Rejeski WJ, For the LIFE study group. Dose of physical activity, physical functioning and disability risk in mobility-limited older adults: Results from the LIFE study randomized trial PLOS One August 2017
- Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Maren, Fragala, MS, Kenny AM, Kiel, DP, Kritchevsky SB, Shardell MD, Dam T-T L, and Vassileva MT. The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates J Gerontol A Biol Sci Med Sci. 2014; 69(5): 547-558
- Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. <u>A short physical performance battery assessing lower extremity function: association with</u> <u>self-reported disability and prediction of mortality and nursing home admission.</u> J Gerontol. 1994 Mar;49(2):M85-94. PubMed PMID: 8126356.
- Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, Espeland MA, Fielding RA, Gill TM, Groessl EJ, King AC, Kritchevsky SB, Manini TM, McDermott MM, Miller ME, Newman AB, Rejeski WJ, Sink KM, Williamson JD; LIFE study investigators. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA. 2014 Jun 18;311(23):2387-96
- R.Pederso-Chamizo R, Gomez-Cabello A, Melendez A, S. Vila-Maldonado, Espino L, Gusi N, Villa G, Casajus JA, Gonzalez-Gross M, Ara I, THE JOURNAL OF NUTRITION, HEALTH & AGING. April 18; 2014: 1-7.
- Gouveia ÉR, Maia JA, Beunen GP, Blimkie CJ, Fena EM, and Freitas DL Functional Fitness and Physical Activity of Portuguese Community-Residing Older Adults Journal of Aging and Physical Activity, 2013, 21, 1-19
- Cruz-Jentoft A et al., Sarcopenia: revised European consensus on definition and diagnosis Age and Ageing, 2018. 0: 1-16
- Marzetti E et al., The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of Eligible participants. Experimental Gerontology, 2018. 113. 48-57